Evaluation of methylphenidate effect on brain growth factor.

Evaluation and comparison of plasma level of brain-derived neurotrophic factor before and after treatment with methylphenidate in children and adolescent with ADHD.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108067237N1

Enrollment

Registered

2011-08-10

Start date

2011-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD. Disturbance of activity and attention

Interventions

6 weeks treatment with effective dosage of methylphenidate.

Treatment - Drugs

6 weeks treatment with effective dosage of methylphenidate

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age below 18; absence of any other axis I diagnosis; absence of any neurological disorder; use of psychothropic drug within the last month; IQ>70. Exclusion criteria: drug discontinue due to side effects(tics, hallucinations, depressed mood, OCD, ...); augmentation of any other psychotropic medication; occuring of any major neurological and psychiatric disorder (eg, depression, bipolare, psychotic disorders); acute and febral disease within current 2weeks.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
BDNF(Brain-derived neurotrophic factor) plasma level. Timepoint: Before treatment, 10 weeks after treatment. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Kousha

Guilan University of Medical Sciences

m-kousha@gums.ac.ir+98 13 1666 6268

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026